72 related articles for article (PubMed ID: 2632803)
1. Effects of interferon-alpha on macrophage activation in patients with ovarian carcinoma and cervical dysplasia.
Fuith LC; Fuchs D; Hausen A; Hetzel H; Reibnegger G; Werner ER; Wachter H
J Clin Lab Immunol; 1989 Jun; 29(2):65-9. PubMed ID: 2632803
[TBL] [Abstract][Full Text] [Related]
2. Preactivated T cells in cancer patients with poor prognosis.
Fuchs DN; Fuith LC; Hausen A; Hetzel H; Reibnegger GJ; Werner ER; Wachter H
Cancer Detect Prev; 1988; 12(1-6):97-103. PubMed ID: 3141055
[TBL] [Abstract][Full Text] [Related]
3. [Results of a phase II study on the treatment of hairy cell leukemias with various doses of alpha-2-recombinant interferon].
Aulitzky W; Gastl G; Troppmair J; Tilg H; Abbrederis K; Nerl C; Flener R; Rokos H; Huber C
Acta Med Austriaca; 1985; 12(5):115-21. PubMed ID: 3832745
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Berek JS; Hacker NF; Lichtenstein A; Jung T; Spina C; Knox RM; Brady J; Greene T; Ettinger LM; Lagasse LD
Cancer Res; 1985 Sep; 45(9):4447-53. PubMed ID: 4028027
[TBL] [Abstract][Full Text] [Related]
5. [The intraperitoneal installation of gamma interferon for the treatment of refractory ovarian carcinoma].
Marth C; Mull R; Gastl G; Herold M; Steiner E; Daxenbichler G; Hetzel H; Flener R; Huber C; Dapunt O
Geburtshilfe Frauenheilkd; 1989 Nov; 49(11):987-91. PubMed ID: 2511058
[TBL] [Abstract][Full Text] [Related]
6. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
[TBL] [Abstract][Full Text] [Related]
7. Leukocyte interferon (IFN alpha) in patients with epithelial ovarian carcinoma.
Freedman RS; Gutterman JU; Wharton JT; Rutledge FN
J Biol Response Mod; 1983; 2(2):133-8. PubMed ID: 6644331
[TBL] [Abstract][Full Text] [Related]
8. Recombinant leukocyte alpha interferon in advanced ovarian carcinoma.
Niloff JM; Knapp RC; Jones G; Schaetzl EM; Bast RC
Cancer Treat Rep; 1985; 69(7-8):895-6. PubMed ID: 4016797
[TBL] [Abstract][Full Text] [Related]
9. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
[TBL] [Abstract][Full Text] [Related]
10. Treatment of dysplasia of the cervical epithelium with an interferon gel.
Møller BR; Johannesen P; Osther K; Ulmsteen U; Hastrup J; Berg K
Obstet Gynecol; 1983 Nov; 62(5):625-9. PubMed ID: 6353302
[TBL] [Abstract][Full Text] [Related]
11. [Clinical study of recombinant interferon alpha-2 (Sch 30500) in advanced gynecological cancers].
Kasamatsu T; Ohmi K; Takeuchi S; Takamizawa H; Matsuzawa M; Kawana T; Ueda K; Kubo H; Tsumuji Y; Kawashima Y
Gan To Kagaku Ryoho; 1985 Aug; 12(8):1656-60. PubMed ID: 3896157
[TBL] [Abstract][Full Text] [Related]
12. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
13. Neopterin as a prognostic indicator in patients with carcinoma of the uterine cervix.
Reibnegger GJ; Bichler AH; Dapunt O; Fuchs DN; Fuith LC; Hausen A; Hetzel HM; Lutz H; Werner ER; Wachter H
Cancer Res; 1986 Feb; 46(2):950-5. PubMed ID: 3940654
[TBL] [Abstract][Full Text] [Related]
14. Significance of urinary neopterine in gynecological oncology: follow-up of patients with ovarian cancer.
Hetzel H; Bichler A; Fuchs D; Hausen A; Reibnegger G; Wachter H
Cancer Detect Prev; 1983; 6(1-2):263-6. PubMed ID: 6883385
[TBL] [Abstract][Full Text] [Related]
15. [Interferon (IFN) therapy (recombinant IFN-alpha-2C or recombinant IFN-gamma) in metastasized hypernephroma].
Kuzmits R; Scheithauer W; Ludwig H; Flener R
Acta Med Austriaca; 1985; 12(5):129-34. PubMed ID: 3938590
[TBL] [Abstract][Full Text] [Related]
16. Exfoliative cytology in the evaluation of interferon treatment of cervical intraepithelial neoplasia.
Hsu C; Choo YC; Seto WH; Pang SW; Tan CY; Merigan TC; Ng MH
Acta Cytol; 1984; 28(2):111-7. PubMed ID: 6583967
[TBL] [Abstract][Full Text] [Related]
17. [Immune activation in patients with ovarian cancers].
Marth C; Moncayo R; Moncayo H; Fuith LC; Daxenbichler G
Gynakol Rundsch; 1990; 30 Suppl 1():63-5. PubMed ID: 2127767
[No Abstract] [Full Text] [Related]
18. Correlation between pretreatment serum levels of neopterin and response to interleukin-2 immunotherapy in cancer patients.
Lissoni P; Barni S; Ardizzoia A; Scardino E; Tancini G; Viganò MG
J Biol Regul Homeost Agents; 1995; 9(1):21-3. PubMed ID: 8553904
[TBL] [Abstract][Full Text] [Related]
19. A study of interactions among markers of macrophage functions in metastatic solid tumors: neopterin levels in relation to those of tumor necrosis factor-alpha and of soluble interleukin-2 receptors.
Lissoni P; Brivio F; Fumagalli L; Galimberti C; Cataldo M; Marsili MT; Brivio O; Barni S; Tancini G; Angelini A
J Biol Regul Homeost Agents; 1994; 8(1):32-5. PubMed ID: 7976492
[TBL] [Abstract][Full Text] [Related]
20. [Urinary excretion of neopterin and plasma levels of interferon gamma in patients with multiple myeloma].
Spicka I; Tomsová Z; Masek Z; Procházka B; Zounar R; Klener P
Vnitr Lek; 1996 Oct; 42(10):665-8. PubMed ID: 8975455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
